 Michael Taravella
Concepts (182)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Phacoemulsification | 8 | 2022 | 109 | 3.330 |
Why?
| | Cataract Extraction | 9 | 2022 | 82 | 1.740 |
Why?
| | Descemet Stripping Endothelial Keratoplasty | 3 | 2022 | 7 | 1.710 |
Why?
| | Lens Implantation, Intraocular | 7 | 2021 | 60 | 1.690 |
Why?
| | Intraoperative Complications | 3 | 2020 | 130 | 1.500 |
Why?
| | Visual Acuity | 7 | 2020 | 282 | 1.440 |
Why?
| | Endothelium, Corneal | 3 | 2022 | 15 | 1.310 |
Why?
| | Keratomileusis, Laser In Situ | 4 | 2020 | 16 | 1.250 |
Why?
| | Myopia | 4 | 2021 | 37 | 1.080 |
Why?
| | Tissue and Organ Harvesting | 3 | 2022 | 72 | 1.030 |
Why?
| | Corneal Diseases | 6 | 2013 | 36 | 1.020 |
Why?
| | Cataract | 4 | 2022 | 200 | 0.970 |
Why?
| | Lenses, Intraocular | 4 | 2021 | 45 | 0.940 |
Why?
| | Cornea | 8 | 2021 | 120 | 0.840 |
Why?
| | Lasers, Excimer | 4 | 2020 | 21 | 0.820 |
Why?
| | Refraction, Ocular | 2 | 2021 | 31 | 0.730 |
Why?
| | Posterior Capsular Rupture, Ocular | 1 | 2020 | 6 | 0.730 |
Why?
| | Lens Capsule, Crystalline | 1 | 2020 | 10 | 0.720 |
Why?
| | Retinal Diseases | 1 | 2020 | 81 | 0.680 |
Why?
| | Angiogenesis Inhibitors | 1 | 2020 | 224 | 0.630 |
Why?
| | Eye Banks | 2 | 2020 | 7 | 0.620 |
Why?
| | Education, Medical, Graduate | 2 | 2014 | 441 | 0.610 |
Why?
| | Adrenergic alpha-1 Receptor Antagonists | 1 | 2016 | 18 | 0.560 |
Why?
| | Tissue Donors | 2 | 2022 | 352 | 0.540 |
Why?
| | Photorefractive Keratectomy | 3 | 2001 | 13 | 0.500 |
Why?
| | Laser Therapy | 1 | 2016 | 106 | 0.490 |
Why?
| | Surgical Flaps | 4 | 2016 | 141 | 0.440 |
Why?
| | Microtomy | 1 | 2013 | 3 | 0.430 |
Why?
| | Descemet Membrane | 3 | 2022 | 5 | 0.430 |
Why?
| | Sulfonamides | 1 | 2016 | 467 | 0.430 |
Why?
| | Scleritis | 3 | 2022 | 18 | 0.420 |
Why?
| | Internship and Residency | 2 | 2014 | 1083 | 0.410 |
Why?
| | Teaching | 1 | 2014 | 245 | 0.380 |
Why?
| | Learning Curve | 1 | 2011 | 71 | 0.360 |
Why?
| | Postoperative Complications | 6 | 2013 | 2325 | 0.360 |
Why?
| | Lasers, Solid-State | 1 | 2010 | 27 | 0.350 |
Why?
| | Capsule Opacification | 1 | 2010 | 27 | 0.350 |
Why?
| | Ophthalmology | 1 | 2011 | 78 | 0.350 |
Why?
| | Retrospective Studies | 11 | 2021 | 13708 | 0.320 |
Why?
| | Aqueous Humor | 4 | 2001 | 31 | 0.320 |
Why?
| | Cell Count | 3 | 2022 | 321 | 0.310 |
Why?
| | Collagen | 3 | 1999 | 443 | 0.300 |
Why?
| | Clinical Competence | 2 | 2014 | 1013 | 0.300 |
Why?
| | Humans | 36 | 2022 | 125131 | 0.260 |
Why?
| | Follow-Up Studies | 6 | 2020 | 4824 | 0.260 |
Why?
| | Drug Delivery Systems | 2 | 1999 | 309 | 0.260 |
Why?
| | Corneal Stroma | 2 | 2001 | 19 | 0.240 |
Why?
| | Prosthesis Design | 2 | 2020 | 296 | 0.230 |
Why?
| | Aged | 10 | 2020 | 20859 | 0.220 |
Why?
| | Male | 18 | 2020 | 60792 | 0.220 |
Why?
| | Conjunctiva | 2 | 2007 | 51 | 0.220 |
Why?
| | Intraocular Pressure | 3 | 2016 | 290 | 0.200 |
Why?
| | Microscopy | 2 | 2022 | 136 | 0.200 |
Why?
| | Iris | 1 | 2001 | 19 | 0.200 |
Why?
| | Hyperopia | 1 | 2001 | 3 | 0.190 |
Why?
| | Cyanoacrylates | 1 | 2001 | 4 | 0.190 |
Why?
| | Tissue Adhesives | 1 | 2001 | 18 | 0.190 |
Why?
| | Refractive Surgical Procedures | 1 | 2021 | 5 | 0.190 |
Why?
| | Air Pollutants, Occupational | 1 | 2001 | 39 | 0.180 |
Why?
| | Corneal Transplantation | 1 | 2020 | 10 | 0.180 |
Why?
| | Keratoconus | 1 | 2020 | 4 | 0.180 |
Why?
| | Intravitreal Injections | 1 | 2020 | 46 | 0.180 |
Why?
| | Rupture | 1 | 2020 | 107 | 0.180 |
Why?
| | Diabetic Retinopathy | 1 | 2022 | 162 | 0.170 |
Why?
| | Ectodermal Dysplasia | 1 | 1999 | 15 | 0.170 |
Why?
| | Calcinosis | 2 | 1994 | 304 | 0.170 |
Why?
| | Ofloxacin | 1 | 1999 | 23 | 0.160 |
Why?
| | Homosexuality, Male | 1 | 2020 | 184 | 0.160 |
Why?
| | Poliovirus | 1 | 1999 | 77 | 0.160 |
Why?
| | Postoperative Period | 1 | 2020 | 317 | 0.160 |
Why?
| | Female | 12 | 2020 | 64889 | 0.160 |
Why?
| | Eye Injuries, Penetrating | 1 | 1998 | 16 | 0.160 |
Why?
| | Boidae | 1 | 1998 | 12 | 0.160 |
Why?
| | Eyelids | 1 | 1998 | 27 | 0.160 |
Why?
| | Tobramycin | 1 | 1998 | 49 | 0.150 |
Why?
| | Aged, 80 and over | 4 | 2020 | 6936 | 0.150 |
Why?
| | Corneal Injuries | 1 | 1998 | 37 | 0.150 |
Why?
| | Pseudallescheria | 1 | 1997 | 3 | 0.150 |
Why?
| | Mycetoma | 1 | 1997 | 6 | 0.150 |
Why?
| | Cost-Benefit Analysis | 1 | 2020 | 578 | 0.150 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2020 | 537 | 0.150 |
Why?
| | Snake Bites | 1 | 1998 | 59 | 0.140 |
Why?
| | Anterior Capsule of the Lens | 1 | 2016 | 2 | 0.140 |
Why?
| | Capsulorhexis | 1 | 2016 | 8 | 0.140 |
Why?
| | Anti-Infective Agents | 1 | 1999 | 244 | 0.130 |
Why?
| | Dexamethasone | 2 | 1998 | 329 | 0.130 |
Why?
| | Lung | 2 | 1999 | 3865 | 0.130 |
Why?
| | Down Syndrome | 1 | 2020 | 403 | 0.120 |
Why?
| | Models, Biological | 1 | 2001 | 1753 | 0.120 |
Why?
| | Prednisolone | 1 | 1994 | 76 | 0.110 |
Why?
| | Safety | 3 | 2001 | 309 | 0.110 |
Why?
| | Operative Time | 1 | 2014 | 115 | 0.110 |
Why?
| | Middle Aged | 8 | 2020 | 29112 | 0.110 |
Why?
| | Herpesvirus 3, Human | 1 | 1997 | 390 | 0.110 |
Why?
| | Hospital Costs | 1 | 2014 | 115 | 0.110 |
Why?
| | Ophthalmic Solutions | 3 | 1999 | 69 | 0.110 |
Why?
| | Operating Rooms | 1 | 2014 | 90 | 0.110 |
Why?
| | Staining and Labeling | 1 | 2013 | 157 | 0.100 |
Why?
| | Anti-Bacterial Agents | 2 | 1998 | 1559 | 0.100 |
Why?
| | Corneal Topography | 2 | 2020 | 5 | 0.090 |
Why?
| | Hospitals, Teaching | 1 | 2011 | 113 | 0.090 |
Why?
| | Anti-Inflammatory Agents | 1 | 1994 | 471 | 0.090 |
Why?
| | Incidence | 2 | 2010 | 2578 | 0.090 |
Why?
| | Methacrylates | 1 | 2010 | 111 | 0.080 |
Why?
| | Cell Survival | 1 | 2013 | 1081 | 0.080 |
Why?
| | Virus Cultivation | 2 | 1999 | 25 | 0.080 |
Why?
| | Adult | 6 | 2020 | 33167 | 0.080 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2022 | 2236 | 0.080 |
Why?
| | Case-Control Studies | 2 | 2016 | 3326 | 0.070 |
Why?
| | United States | 2 | 2020 | 13613 | 0.070 |
Why?
| | Optic Neuropathy, Ischemic | 1 | 2006 | 30 | 0.070 |
Why?
| | Polymers | 1 | 2010 | 476 | 0.070 |
Why?
| | Administration, Topical | 2 | 1998 | 157 | 0.070 |
Why?
| | Surgical Wound Infection | 2 | 1999 | 263 | 0.060 |
Why?
| | Drug Therapy, Combination | 2 | 1998 | 1006 | 0.060 |
Why?
| | Fibroblasts | 2 | 1999 | 859 | 0.060 |
Why?
| | Time Factors | 1 | 2014 | 6780 | 0.050 |
Why?
| | Polypropylenes | 1 | 2022 | 18 | 0.050 |
Why?
| | Sutures | 1 | 2022 | 64 | 0.050 |
Why?
| | Mechanics | 1 | 2001 | 1 | 0.050 |
Why?
| | Miosis | 1 | 2001 | 3 | 0.050 |
Why?
| | Iris Diseases | 1 | 2001 | 5 | 0.050 |
Why?
| | Blinking | 1 | 2001 | 8 | 0.050 |
Why?
| | Glucocorticoids | 2 | 1998 | 554 | 0.050 |
Why?
| | Finite Element Analysis | 1 | 2001 | 67 | 0.050 |
Why?
| | Rupture, Spontaneous | 1 | 2001 | 19 | 0.050 |
Why?
| | Environmental Pollution | 1 | 2001 | 20 | 0.050 |
Why?
| | Rheology | 1 | 2001 | 94 | 0.050 |
Why?
| | Adolescent | 3 | 2020 | 19411 | 0.050 |
Why?
| | Volatilization | 1 | 2001 | 65 | 0.050 |
Why?
| | Anterior Chamber | 1 | 2001 | 21 | 0.050 |
Why?
| | Aberrometry | 1 | 2021 | 9 | 0.050 |
Why?
| | Colorado | 2 | 2020 | 4471 | 0.050 |
Why?
| | Optics and Photonics | 1 | 2021 | 45 | 0.050 |
Why?
| | Biometry | 1 | 2021 | 68 | 0.050 |
Why?
| | Corneal Pachymetry | 1 | 2020 | 16 | 0.040 |
Why?
| | Young Adult | 2 | 2020 | 11384 | 0.040 |
Why?
| | Respiration | 1 | 2001 | 201 | 0.040 |
Why?
| | Particle Size | 1 | 2001 | 353 | 0.040 |
Why?
| | Nuclear Family | 1 | 1999 | 54 | 0.040 |
Why?
| | Smoke | 1 | 2001 | 146 | 0.040 |
Why?
| | Canada | 1 | 2020 | 359 | 0.040 |
Why?
| | Embryo, Mammalian | 1 | 1999 | 226 | 0.040 |
Why?
| | Reoperation | 1 | 2001 | 571 | 0.040 |
Why?
| | Biological Dressings | 1 | 1998 | 3 | 0.040 |
Why?
| | Trifluridine | 1 | 1998 | 3 | 0.040 |
Why?
| | Pterygium | 1 | 1997 | 4 | 0.040 |
Why?
| | Eye Enucleation | 1 | 1997 | 10 | 0.040 |
Why?
| | Sclera | 1 | 1997 | 37 | 0.040 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 1999 | 502 | 0.040 |
Why?
| | Computer Simulation | 1 | 2001 | 953 | 0.040 |
Why?
| | Microbial Sensitivity Tests | 1 | 1998 | 310 | 0.040 |
Why?
| | Ambulatory Care | 1 | 2001 | 511 | 0.040 |
Why?
| | Prospective Studies | 2 | 1999 | 6818 | 0.030 |
Why?
| | Severity of Illness Index | 2 | 2007 | 2848 | 0.030 |
Why?
| | Hospitals, Pediatric | 1 | 2020 | 517 | 0.030 |
Why?
| | Cytomegalovirus Retinitis | 1 | 1996 | 17 | 0.030 |
Why?
| | DNA, Viral | 1 | 1997 | 360 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 1999 | 1431 | 0.030 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 1996 | 117 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 1997 | 1042 | 0.030 |
Why?
| | Immunosuppressive Agents | 1 | 1997 | 693 | 0.030 |
Why?
| | Ultrasonography | 1 | 1997 | 757 | 0.030 |
Why?
| | Antiviral Agents | 1 | 1998 | 673 | 0.030 |
Why?
| | Ultrasonic Therapy | 1 | 1991 | 17 | 0.020 |
Why?
| | Cells, Cultured | 1 | 1999 | 4159 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2016 | 3047 | 0.020 |
Why?
| | Infant, Newborn | 1 | 1999 | 5456 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2020 | 5061 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 1997 | 2539 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2001 | 9790 | 0.020 |
Why?
| | Arteritis | 1 | 2006 | 27 | 0.020 |
Why?
| | Infant | 1 | 1999 | 8625 | 0.020 |
Why?
| | Child, Preschool | 1 | 2020 | 9938 | 0.020 |
Why?
| | Suture Techniques | 1 | 2007 | 137 | 0.020 |
Why?
| | Child | 1 | 2020 | 20014 | 0.010 |
Why?
| | Animals | 2 | 1998 | 34345 | 0.010 |
Why?
| | Arthritis, Rheumatoid | 1 | 2007 | 1001 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 1998 | 196 | 0.010 |
Why?
| | Drug Carriers | 1 | 1998 | 119 | 0.010 |
Why?
| | Swine | 1 | 1998 | 786 | 0.010 |
Why?
| | Macrophages | 1 | 1996 | 1333 | 0.010 |
Why?
|
|
Taravella's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|